Clinical Trials Logo

Filter by:
NCT ID: NCT03887520 Completed - Clinical trials for Cardiovascular Disease and Lipoprotein(a)

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Start date: November 27, 2018
Phase: N/A
Study type: Interventional

The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).

NCT ID: NCT03877224 Completed - Clinical trials for Heart Failure With Preserved Ejection Fraction (HFpEF)

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Start date: April 4, 2019
Phase: Phase 3
Study type: Interventional

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF)

NCT ID: NCT03871816 Completed - Clinical trials for Metastatic Prostate Cancer

A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

Start date: April 22, 2019
Phase:
Study type: Observational

The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair gene defects in a population of men with metastatic Prostate Cancer (PC) and to use the reported DNA-repair gene defects to assess biomarker eligibility for niraparib interventional studies.

NCT ID: NCT03859427 Completed - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

ARROW2
Start date: May 8, 2019
Phase: Phase 3
Study type: Interventional

Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.

NCT ID: NCT03850483 Completed - Psoriasis Clinical Trials

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

Start date: April 8, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. The duration of study participation will be approximately 22 weeks, including up to a 6 week screening period, 12 week treatment period, and approximately 4 week follow up period. Approximately 280 participants are planned to be randomized into the study.

NCT ID: NCT03845517 Completed - Clinical trials for Systemic Lupus Erythematosus

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Start date: April 18, 2019
Phase: Phase 2
Study type: Interventional

Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.

NCT ID: NCT03840148 Completed - Clinical trials for Urinary Tract Infections

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

CERTAIN-1
Start date: August 7, 2019
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.

NCT ID: NCT03831880 Completed - Clinical trials for Growth Hormone Deficiency

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

Start date: February 7, 2019
Phase: Phase 3
Study type: Interventional

This is an open label randomized 24 week crossover trial assessing the treatment burden of a weekly growth hormone injection regimen (somatrogon) compared to a daily growth hormone injection regimen (Genotropin). Approximately 90 children with growth hormone deficiency who have been stable on treatment with daily Genotropin will be enrolled.

NCT ID: NCT03823300 Completed - Clinical trials for Wet Macular Degeneration

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Start date: March 11, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).

NCT ID: NCT03814785 Completed - Follicular Lymphoma Clinical Trials

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

ASSIST_FL
Start date: December 1, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-treatment to patients who receive MabThera-treatment.